Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23042886 | 0.78 | PKM (0.35) | MAPK1CDC7PKML3MBTL1HSD17B10 | |
| SCHEMBL4421374 | 0.77 | HTT (0.39) | MAPK1L3MBTL1TP53HSD17B10USP2 | |
| SCHEMBL13787555 | 0.77 | CDC7 (0.36) | HCAR2MAPK1CDC7HSD17B10KDM4E | |
| SCHEMBL13056608 | 0.69 | CDC7 (0.36) | HCAR2CDC7HSD17B10ADORA3ADORA2A | |
| SCHEMBL7718725 | 0.68 | KDM4E (0.44) | PKMPOLBKDM4ELMNAADORA3 | |
| SCHEMBL2822746 | 0.67 | HCAR2 (0.43) | HCAR2PKML3MBTL1TP53HSD17B10 | |
| SCHEMBL28275637 | 0.66 | KDM4E (0.42) | PKMPOLBKDM4ELMNAADORA3 | |
| SCHEMBL6500732 | 0.66 | CYP2C19 (0.46) | HCAR2CDC7L3MBTL1HSD17B10TSHR | |
| SCHEMBL28251799 | 0.66 | HCAR2 (0.70) | HCAR2HSD17B10 | |
| SCHEMBL20399747 | 0.66 | PDPK1 (0.33) | PKMKDM4ELMNAADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397351-B1 | PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| EP-1345609-B1 | TETRAHYDRO-(BENZO OR THIENO)-AZEPINE-PYRAZINE AND TRIAZINE DERIVATIVES AS MGLUR 1 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| EP-1397351-A1 | PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-17 | — | — | EP | disclosed |
| US-6673795-B2 | SUCH AS 6-(4-(4-FLUORO-PHENYL)-PIPERAZIN-1-YL)-2-METHYL-5-NITRO-3-(2,2,2-TRIFLUORO -ETHYL)-3H-PYRIMIDIN-4-ONE, WHICH ARE METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS USEFUL IN TREATING PSYCHOLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. | 2004-01-06 | — | — | US | disclosed |
| EP-1345609-A1 | TETRAHYDRO-(BENZO OR THIENO)-AZEPINE-PYRAZINE AND TRIAZINE DERIVATIVES AS MGLUR 1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-24 | — | — | EP | disclosed |
| US-6586422-B2 | For therapy and prophylaxis of acute and/or chronic neurological disorders | HOFFMAN-LA ROCHE INC. | 2003-07-01 | — | — | US | disclosed |
| US-20030060466-A1 | Pyrimidine, pyrazine and triazine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-27 | — | — | US | disclosed |
| WO-2002098864-A1 | PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-12 | — | — | WO | disclosed |
| US-20020123488-A1 | Pyrazine and triazine derivatives of 1,2,4,5-tetrahydro-Benzo or Thieno [d] azepine | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-05 | — | — | US | disclosed |
| WO-2002051418-A1 | TETRAHYDRO-(BENZO OR THIENO)-AZEPINE-PYRAZINE AND TRIAZINE DERIVATIVES AS MGLUR 1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123488-A1 | Pyrazine and triazine derivatives of 1,2,4,5-tetrahydro-Benzo or Thieno [d] azepine | GRM5, GRIK5, GRM1 | HCAR2 196/4885MAPK1 1691/4885CDC7 4508/4885 |
| US-20030060466-A1 | Pyrimidine, pyrazine and triazine derivatives | P2RX5, IL5, P2RX2 | HCAR2 1256/4885MAPK1 1111/4885CDC7 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.